Immunocore Financial Ratios
NASDAQ: IMCRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
29.39+0.30 (+1.03%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunocore ratio analysis
Immunocore earned a net margin of -8.9% in FY 2025, up from -16.5% a year earlier. Gross margin was 98.7% compared with a median of 99.5% over the prior 4 years. Return on equity reached -9.3%, meaning Immunocore generated -0.09 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Immunocore financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Price / sales | 4.25 | 4.81 | 13.39 | 14.96 | 39.88 |
| Price / book | 4.46 | 4.14 | 9.06 | 7.70 | 6.22 |
| Gross margin | 98.7% | 99.1% | 99.6% | 99.4% | 100.0% |
| Operating margin | -11.3% | -22.7% | -23.9% | -29.7% | -478.5% |
| Net margin | -8.9% | -16.5% | -22.2% | -30.1% | -493.4% |
| Free cash flow margin | -3.8% | 6.7% | -1.0% | -29.5% | -396.0% |
| Return on equity (ROE) | -9.3% | -14.2% | -15.0% | -15.5% | -77.0% |
| Return on assets (ROA) | -3.3% | -5.1% | -9.3% | -10.0% | — |
| Current ratio | 4.04 | 4.38 | 3.80 | 4.70 | — |
| Revenue growth | 29.0% | 24.4% | 43.1% | 377.9% | — |